<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210740</url>
  </required_header>
  <id_info>
    <org_study_id>AD-AM001-AK1</org_study_id>
    <nct_id>NCT03210740</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis</brief_title>
  <official_title>A Phase 2, Single-Center, Randomized, Double- Blind, Parallel-Group, Vehicle-Controlled Study Evaluating the Efficacy and Safety of AM001 Cream in the Treatment of Actinic Keratosis (AK) Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AmDerma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AmDerma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the
      treatment of Actinic Keratosis (AK) Lesions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2, Single-Center, Randomized, Double- Blind, Parallel-Group, Vehicle-Controlled Study
      Evaluating the Efficacy and Safety of AM001 Cream in the Treatment of Actinic Keratosis (AK)
      Lesions
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clearance of all lesions</measure>
    <time_frame>8 weeks post treatment</time_frame>
    <description>(100 % of all AK lesions cleared) 8 weeks post treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clearance of all baseline lesions weeks of treatment</measure>
    <time_frame>16 weeks</time_frame>
    <description>(100% of baseline AK lesions cleared) after 16 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete clearance of all lesions</measure>
    <time_frame>12 weeks</time_frame>
    <description>(100% of baseline AK lesions cleared) after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete clearance of all lesions</measure>
    <time_frame>8 weeks</time_frame>
    <description>(100% of baseline AK lesions cleared) after 8 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>AM001 Cream, 7.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A white to off-white Cream free from any foreign particles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A white to off-white Cream free from any foreign particles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM001 Cream, 7.5%</intervention_name>
    <description>Active Cream</description>
    <arm_group_label>AM001 Cream, 7.5%</arm_group_label>
    <other_name>Potassium Dobesilate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>Placeo</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <other_name>Placebo Cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must provide written informed consent.

          2. Subject must be male or non-pregnant females of any race, and any skin type aged 18 to
             80 years both inclusive.

          3. Subject has 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic,
             nonhypertrophic AK lesions, each at least 4 mm in diameter within a 25cmÂ² contiguous
             treatment area on the face or the balding scalp.

          4. Subject is willing to avoid exposure to sunlight, use of tanning booths, sunlamps, or
             nonprescription UV (ultra-violate) light sources during the study period.ooths,
             sunlamps, or nonprescription UV (ultra-violate) light sources during the study period.

          5. If female subject of childbearing potential, the subject must have a negative urine
             pregnancy test at Visit 1/ Screening and must have been using an acceptable form of
             birth control for at least 2 months prior to Visit 1/ Screening and is willing to
             continue birth control during the study.

          6. Subject must be willing and able to understand and comply with the requirements of the
             study, apply the assigned investigational product as instructed, return for the
             required study visits, comply with therapy prohibitions.

          7. Subject must be in good health, as confirmed by medical history and physical exam, and
             free from any clinically significant disease/condition, other than actinic keratosis,
             that might interfere with the study evaluations.

        Exclusion Criteria:

          1. Subject has very thick and/or hyperkeratotic actinic keratosis AK lesions in the
             treatment area.

          2. Subject has used topical treatment of actinic keratosis in the treatment area with
             5-fluorouracil, imiquimod, diclofenac, corticosteroids or retinoids within 1 month
             prior to Visit 2/Baseline or during the study.

          3. Subject has used treatment with PDT (photodynamic therapy) or physical therapies (e.
             g. cryotherapy, curettage or surgical treatment) in the treatment area within 1 month
             prior to Visit 2/Baseline or during the study.

          4. Subject has used chemical peel, dermabrasion, laser abrasion, PUVA (prosalen plus
             ultraviolet A) therapy or UVB therapy within 6 months prior to Visit 2/Baseline or
             during the study.

          5. Subject has used immunomodulators or immunosuppressive therapies, interferon, oral
             corticosteroids, oral retinoids or cytotoxic drugs within 1 month prior to Visit
             2/Baseline or during the study.

          6. Subject has untreated basal cell carcinoma, squamous cell carcinoma or melanoma in the
             treatment area.

          7. Subject has suntan or tattoos that may interfere with the assessments in the treatment
             area.

          8. Subject has dermatological diseases in the treatment area that may interfere with the
             assessments, e.g. acute skin inflammation, atopic dermatitis, eczema, rosacea,
             psoriasis, seborrheic dermatitis, peri-oral dermatitis or hyperpigmentation.

          9. Subject who consumes excessive amount of alcohol, abuse or have any condition that in
             the investigator's opinion would compromise compliance, with this protocol.

         10. Subject has history of malignancy not in remission for at least 5 years excluding
             basal cell carcinoma and nonperiorificial squamous cell carcinoma of the skin.

         11. Female subject who is pregnant, nursing or planning a pregnancy within the study
             participation period

         12. Subject has symptoms of a clinically significant illness that may influence the
             outcome of the study in the 4 weeks prior to Visit 1/Screening.

         13. Subject has participated in another clinical trial involving investigational product
             or device in the 4 weeks prior to Visit 1/Screening.

         14. Subject has known allergic reactions to components of the investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irshad Haque</last_name>
    <phone>631-633-2476</phone>
    <email>ihaque@amneal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AmDerma Pharmaceuticals, LLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irshad Haque</last_name>
      <phone>631-633-2476</phone>
      <email>ihaque@amneal.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

